NOV (NOV)
(Delayed Data from NYSE)
$12.66 USD
-0.03 (-0.24%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $12.72 +0.06 (0.47%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, NOV Inc. has a PEG ratio of 3.00 compared to the Oil and Gas - Mechanical and and Equipment industry's PEG ratio of 3.76.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NOV 12.66 -0.03(-0.24%)
Will NOV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NOV
Here's Why Investors Should Consider Selling NOV Stock Now
NOV Secures Key Contract for Argentina's First FLNG Project
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nov Inc. (NOV) Down 1.2% Since Last Earnings Report: Can It Rebound?
NOV Stock Drops 19% in the Past Six Months: Time to Hold or Exit?
NOV Q2 Earnings Miss, Revenues Beat Estimates, Both Decrease Y/Y
Other News for NOV
Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat
50 Day Moving Average Resistance appears for NOV after 0.94% move
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
Bernstein Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Novo Nordisk announces FDA approval of Rybelsus